Tirzepatide Diarrhea: Why It Happens and How Long It Lasts
Tirzepatide diarrhea is one of the most common side effects of the drug, reported by 19% to 23% of people on Zepbound in its label trials against 8% on placebo. The label says most cases came while the dose was being raised, and became less common over time.
If loose stools started soon after a dose increase, that matches what the label describes. The Medication Guide says to drink fluids and to tell your healthcare provider right away if diarrhea does not go away.
Short answer
- When it tends to show up
- The Zepbound label says most cases came during dose increases and decreased over time. A 2026 analysis of adverse event reports found a median onset of 16 days.
- How common it is, by the label
- In the Zepbound label's weight trials, 19% to 23% of people on the drug reported diarrhea, against 8% on placebo.
- What the label says to do
- The Medication Guide says diarrhea can cause fluid loss, and that drinking fluids helps reduce the chance of dehydration.
- When to call a healthcare provider
- Right away if diarrhea does not go away, says the Medication Guide. The label also lists persistent or severe belly pain, sometimes spreading to the back, as a sign of pancreatitis.
Sources: Zepbound FDA label and Medication Guide; PLoS One 2026, pharmacovigilance analysis
Diarrhea on the Zepbound and Mounjaro labels
Yes. Both the Zepbound and Mounjaro FDA labels list diarrhea as a common side effect.
The Zepbound Medication Guide lists nausea, diarrhea, vomiting, constipation, stomach pain and indigestion among its most common side effects. Diarrhea comes second on that list, after nausea.
How common is diarrhea on tirzepatide?
In the Zepbound label's weight trials, diarrhea was reported by 19% to 23% of people on the drug and 8% on placebo. It rose a little with each dose.
The Zepbound label's side effect table for its weight trials lists diarrhea in:
- Placebo: 8%
- Zepbound 5 mg: 19%
- Zepbound 10 mg: 21%
- Zepbound 15 mg: 23%
Disclaimer: these are trial doses, not a recommendation. Dose decisions belong with a licensed clinician.
Stomach side effects by dose in the Zepbound trials
In the Zepbound label's weight trials, severe stomach and gut side effects affected 3.1% or fewer on any dose, and 4.3% or fewer stopped because of them. The table puts every figure in one place.
| Measure | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Diarrhea (Zepbound weight trials) | 8% | 19% | 21% | 23% |
| Any stomach or gut side effect | 30% | 56% | 56% | 56% |
| Severe stomach or gut side effect | 1% | 1.7% | 2.5% | 3.1% |
| Stopped because of stomach or gut side effects | 0.5% | 1.9% | 3.3% | 4.3% |
| Diarrhea (Mounjaro diabetes trials) | 9% | 12% | 13% | 17% |
The first four rows are from the Zepbound weight trials. The last row is from the Mounjaro type 2 diabetes trials.
Disclaimer: these are trial doses, not a recommendation. Dose decisions belong with a licensed clinician.
Sources: Zepbound FDA label and Medication Guide; Mounjaro FDA label
Mounjaro diarrhea in the type 2 diabetes trials
In the Mounjaro label's type 2 diabetes trials, diarrhea was reported by 12% to 17% of people on the drug and 9% on placebo. Mounjaro is the same medicine as Zepbound, tirzepatide.
By dose, the Mounjaro label lists 12%, 13% and 17% on the 5 mg, 10 mg and 15 mg doses. Like the Zepbound label, it says most reports came during dose escalation and decreased over time. For how the two brands compare, see is Zepbound the same as Mounjaro.
Sources: Mounjaro FDA label
When does tirzepatide diarrhea start, and how long does it last?
The Zepbound label says most diarrhea came during dose increases and decreased over time. No label gives a number of days or weeks for how long it lasts.
- The Zepbound label says the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time.
- The SURMOUNT-1 trial paper says the most common side effects were stomach and gut problems. Most were mild to moderate, and most happened during dose escalation.
- A 2026 analysis of adverse event reports for tirzepatide found most stomach and gut events started within 3 months. The median time to start was 16 days.
How to avoid diarrhea on Zepbound? The label gives no prevention plan. It only reports that most cases came during the dose steps and eased over time.
Dose escalation means the steps up from the starting dose. The steps are set out in the tirzepatide dosage guide.
Sources: Zepbound FDA label and Medication Guide; SURMOUNT-1, N Engl J Med 2022; PLoS One 2026, pharmacovigilance analysis
Why does tirzepatide cause diarrhea?
The labels tie it to the dose increases, when most cases happened, but they do not name a deeper cause.
In the Zepbound label's weight trials, 56% of people on each Zepbound dose had some stomach or gut side effect, against 30% on placebo.
What the label says to do about diarrhea
The Zepbound Medication Guide says to drink fluids to help reduce the chance of dehydration, and to tell a healthcare provider right away about diarrhea that does not go away. It gives no other plan.
The Medication Guide says diarrhea, nausea and vomiting may cause a loss of fluids, called dehydration, which may cause kidney problems. It says it is important to drink fluids to help reduce the chance of dehydration.
The label also describes reports, made after approval, of sudden (acute) kidney injury. It says most of these happened in people whose stomach side effects, such as nausea, vomiting or diarrhea, led to dehydration.
When the label says to call: pancreatitis signs and diarrhea that will not stop
The Zepbound label describes pancreatitis signs as persistent or severe belly pain, sometimes spreading to the back, with or without nausea or vomiting. It also names diarrhea that does not go away as a reason to call.
Diarrhea that does not go away: the Medication Guide says to tell your healthcare provider right away if you have nausea, vomiting or diarrhea that does not go away.
Signs of pancreatitis: the label describes these as persistent or severe belly pain, sometimes spreading to the back, which may or may not come with nausea or vomiting.
For other side effects, see does tirzepatide make you tired, does tirzepatide cause hair loss and our GLP-1 side effects guide.
How tirzepatide compares with other diabetes drugs
Among GLP-1 type drugs for type 2 diabetes, a 2025 network meta-analysis found tirzepatide had the highest risk of diarrhea.
That review compared stomach side effects of these drugs in type 2 diabetes. It found tirzepatide had the highest risk of nausea and diarrhea. Dulaglutide and lixisenatide had the lowest risks. It also found semaglutide had a significantly higher risk of diarrhea than the other GLP-1 receptor agonists.
A 2026 analysis of adverse event reports for tirzepatide found nausea (27.7%) and diarrhea (12.8%) were the most frequently reported events. Reports like these show what people report, not how often it happens to everyone.
Sources: Front Pharmacol 2025, network meta-analysis; PLoS One 2026, pharmacovigilance analysis
Diarrhea reports with compounded tirzepatide
The FDA says some reports of diarrhea may be related to compounded semaglutide or tirzepatide prescribed above the label dose.
The FDA has a page on its concerns with unapproved GLP-1 drugs. It says it has received adverse event reports that may be related to compounded semaglutide or tirzepatide given in doses beyond the FDA-approved label. Some of the adverse events are serious, and some patients reported seeking medical attention for symptoms including nausea, vomiting, diarrhea, abdominal pain and constipation.
What the sources do not say about tirzepatide diarrhea
Three common claims about tirzepatide diarrhea have no official or primary source behind them. Here is what we could not confirm.
How long diarrhea lasts for one person
No label or study we found gives a time in days or weeks. The labels only say most cases came during dose increases and decreased over time.
A diet or treatment plan
The labels do not give one. Beyond drinking fluids and telling a healthcare provider about diarrhea that does not go away, how to manage it is a question for the prescriber.
Whether to stop a medicine
The sources here do not say when to stop tirzepatide. That decision belongs with a licensed clinician.
Sources: Zepbound FDA label and Medication Guide; Mounjaro FDA label
Tirzepatide diarrhea questions
Does Zepbound cause diarrhea?+
Yes, it is one of the most common side effects. In the Zepbound weight trials, diarrhea was reported by 8% on placebo and by 19%, 21% and 23% on the 5 mg, 10 mg and 15 mg doses. Disclaimer: these are trial doses, not a recommendation. Dose decisions belong with a licensed clinician.
How long does tirzepatide diarrhea last?+
The labels give no exact time. The Zepbound label says the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. A 2026 analysis of adverse event reports found most stomach and gut events started within 3 months, with a median onset of 16 days.
Does Mounjaro cause diarrhea?+
Yes. In the Mounjaro type 2 diabetes trials, diarrhea was reported by 9% on placebo and by 12%, 13% and 17% on the 5 mg, 10 mg and 15 mg doses. The Mounjaro label also says most reports came during dose escalation and decreased over time. Disclaimer: these are trial doses, not a recommendation. Dose decisions belong with a licensed clinician.
What should I do if I have diarrhea from tirzepatide?+
The Zepbound Medication Guide says diarrhea, nausea and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems, and that it is important to drink fluids to help reduce the chance of dehydration. It says to tell your healthcare provider right away about nausea, vomiting or diarrhea that does not go away.
What are the symptoms of tirzepatide pancreatitis?+
The Zepbound label describes signs of acute pancreatitis as persistent or severe abdominal pain, sometimes spreading to the back, which may or may not come with nausea or vomiting.
Which diabetes medicines are most likely to cause diarrhea?+
A 2025 network meta-analysis of drugs for type 2 diabetes found tirzepatide had the highest risk of nausea and diarrhea, while dulaglutide and lixisenatide had the lowest. It also found semaglutide had a significantly higher risk of diarrhea than other GLP-1 receptor agonists.
Sources: Zepbound FDA label and Medication Guide; Mounjaro FDA label; PLoS One 2026, pharmacovigilance analysis; Front Pharmacol 2025, network meta-analysis
Related tirzepatide guides
This guide is for educational purposes only and is not medical advice. It describes what drug labels, FDA guidance and published studies report about tirzepatide and diarrhea. Questions about your own symptoms or medicine belong with a licensed clinician.